Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-205solekizumabPlaque psoriasisImmunology · Antibody
Pediatric study ongoing
CLV-219teravolumabHidradenitis suppurativaImmunology · Antibody
Regulatory decision H2 2027
CLV-211corvatinibCrohn's diseaseImmunology · Small molecule
Phase 3 enrollment complete
CLV-226Atopic dermatitisImmunology · Antibody
Phase 2b readout Q4 2026
CLV-233LupusImmunology · Cell therapy
First patient dosed
Pipeline as of September 30, 2026. Programs and data are fictional.